Patents by Inventor Dietmar Leipert

Dietmar Leipert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FAP-activated anti-tumor compounds
    Publication number: 20030232742
    Abstract: The invention relates to a prodrug that is capable of being converted into a drug by the catalytic action of human fibroblast activation protein (FAP&agr;), said prodrug is chemically stable under physiological conditions and can be used for the manufacture of physically stable aqueous formulations. It has a cleavage site which is recognised by FAP&agr;, and the drug released by the enzymatic activity of FAP&agr; is cytotoxic or cytostatic under physiological conditions.
    Type: Application
    Filed: November 9, 2001
    Publication date: December 18, 2003
    Inventors: Stefan Peters, Dietmar Leipert, Christian Eickmeier, John Edward Park, Martin Lenter, Pilar Garin-Chesa, Juergen Mack
  • FAP-activated anti-tumour compounds
    Patent number: 6613879
    Abstract: The invention relates to a prodrug that is capable of being converted into a drug by the catalytic action of human fibroblast activation protein (FAP&agr;), said prodrug having a cleavage site which is recognised by FAP&agr;, and said drug being cytotoxic or cytostatic under physiological conditions.
    Type: Grant
    Filed: April 21, 2000
    Date of Patent: September 2, 2003
    Assignees: Boehringer Ingelheim Pharma KG, Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Raymond A. Firestone, Wolfgang J. Rettig, Martin Lenter, Stefan Peters, Pilar Garin-Chesa, Juergen Mack, Dietmar Leipert, John E. Park, Leila A. Telan
  • FAP-activated anti-tumor compounds
    Publication number: 20030055052
    Abstract: The invention relates to a prodrug that is capable of being converted into a drug by the catalytic action of human fibroblast activation protein (FAP&agr;), said prodrug having a cleavage site which is recognised by FAP&agr;, and said drug being cytotoxic or cytostatic under physiological conditions.
    Type: Application
    Filed: November 9, 2001
    Publication date: March 20, 2003
    Inventors: Stefan Peters, Dietmar Leipert, John Edward Park, Martin Lenter, Pilar Garin-Chesa
  • FAP-activated anti-tumor compounds
    Publication number: 20020155565
    Abstract: The invention relates to a prodrug that is capable of being converted into a drug by the catalytic action of human fibroblast activation protein (FAP&agr;), said prodrug having a cleavage site which is recognized by FAP&agr;, and said drug being cytotoxic or cytostatic under physiological conditions, wherein said prodrug comprises an oligomeric part comprising at least two amino carboxylic residues, and a cytotoxic or cytostatic part, wherein the C-terminal amino carboxylic residue of the oligomeric part is an acyclic amino acid, the nitrogen atom of the amino function thereof is attached to a substituent being different from a hydrogen atom, and the C-terminal carboxy function thereof is linked to the cytotoxic or cytostatic part by an amide bond.
    Type: Application
    Filed: November 9, 2001
    Publication date: October 24, 2002
    Inventors: Pilar Garin-Chesa, John Edward Park, Stefan Peters, Dietmar Leipert, Juergen Mack, Martin Lenter